These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34819133)

  • 1. Development of a chemogenomics library for phenotypic screening.
    Dafniet B; Cerisier N; Boezio B; Clary A; Ducrot P; Dorval T; Gohier A; Brown D; Audouze K; Taboureau O
    J Cheminform; 2021 Nov; 13(1):91. PubMed ID: 34819133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Introduction to Chemogenomics.
    Chaikuad A; Merk D
    Methods Mol Biol; 2023; 2706():1-10. PubMed ID: 37558937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of chemogenomic library screening in drug discovery.
    Jones LH; Bunnage ME
    Nat Rev Drug Discov; 2017 Apr; 16(4):285-296. PubMed ID: 28104905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating inflammatory biomarker analysis and artificial-intelligence-enabled image-based profiling to identify drug targets for intestinal fibrosis.
    Yu S; Kalinin AA; Paraskevopoulou MD; Maruggi M; Cheng J; Tang J; Icke I; Luo Y; Wei Q; Scheibe D; Hunter J; Singh S; Nguyen D; Carpenter AE; Horman SR
    Cell Chem Biol; 2023 Sep; 30(9):1169-1182.e8. PubMed ID: 37437569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How polypharmacologic is each chemogenomics library?
    Ni E; Kwon E; Young LM; Felsovalyi K; Fuller J; Cardozo T
    Future Drug Discov; 2020 Feb; 2(1):FDD26. PubMed ID: 32149277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linking chemicals, genes and morphological perturbations to diseases.
    Cerisier N; Dafniet B; Badel A; Taboureau O
    Toxicol Appl Pharmacol; 2023 Feb; 461():116407. PubMed ID: 36736439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation phenotypic screening.
    Warchal SJ; Unciti-Broceta A; Carragher NO
    Future Med Chem; 2016 Jul; 8(11):1331-47. PubMed ID: 27357617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database.
    Wang L; Ma C; Wipf P; Liu H; Su W; Xie XQ
    AAPS J; 2013 Apr; 15(2):395-406. PubMed ID: 23292636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens.
    Bornot A; Blackett C; Engkvist O; Murray C; Bendtsen C
    J Biomol Screen; 2014 Jun; 19(5):696-706. PubMed ID: 24441646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemogenomics: a discipline at the crossroad of high throughput technologies, biomarker research, combinatorial chemistry, genomics, cheminformatics, bioinformatics and artificial intelligence.
    Maréchal E
    Comb Chem High Throughput Screen; 2008 Sep; 11(8):583-6. PubMed ID: 18795877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need.
    Hughes RE; Elliott RJR; Dawson JC; Carragher NO
    Cell Chem Biol; 2021 Mar; 28(3):338-355. PubMed ID: 33740435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pluripotent Stem Cell-Derived Hepatocytes Phenotypic Screening Reveals Small Molecules Targeting the CDK2/4-C/EBPα/DGAT2 Pathway Preventing ER-Stress Induced Lipid Accumulation.
    Parafati M; Bae SH; Kirby RJ; Fitzek M; Iyer P; Engkvist O; Smith DM; Malany S
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33334026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic drug discovery: a case for thymosin alpha-1.
    Garaci E; Paci M; Matteucci C; Costantini C; Puccetti P; Romani L
    Front Med (Lausanne); 2024; 11():1388959. PubMed ID: 38903817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Image-based high-content screening in drug discovery.
    Lin S; Schorpp K; Rothenaigner I; Hadian K
    Drug Discov Today; 2020 Aug; 25(8):1348-1361. PubMed ID: 32561299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches.
    Lee JA; Berg EL
    J Biomol Screen; 2013 Dec; 18(10):1143-55. PubMed ID: 24080259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space.
    van der Horst E; Peironcely JE; van Westen GJ; van den Hoven OO; Galloway WR; Spring DR; Wegner JK; van Vlijmen HW; Ijzerman AP; Overington JP; Bender A
    Curr Top Med Chem; 2011; 11(15):1964-77. PubMed ID: 21470175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding chemogenomic space using chemoproteomics.
    Jones LH
    Bioorg Med Chem; 2019 Aug; 27(15):3451-3453. PubMed ID: 31221609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Silico Chemogenomics Drug Repositioning Strategies for Neglected Tropical Diseases.
    Andrade CH; Neves BJ; Melo-Filho CC; Rodrigues J; Silva DC; Braga RC; Cravo PVL
    Curr Med Chem; 2019; 26(23):4355-4379. PubMed ID: 29521204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks.
    Swamidass SJ; Schillebeeckx CN; Matlock M; Hurle MR; Agarwal P
    J Biomol Screen; 2014 Jun; 19(5):782-90. PubMed ID: 24563424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systems pharmacology strategies for drug discovery and combination with applications to cardiovascular diseases.
    Li P; Chen J; Wang J; Zhou W; Wang X; Li B; Tao W; Wang W; Wang Y; Yang L
    J Ethnopharmacol; 2014; 151(1):93-107. PubMed ID: 23850710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.